
|Articles|September 1, 2007
- Psychiatric Times Vol 24 No 10
- Volume 24
- Issue 10
New Patient
Author(s)Richard M. Berlin, MD
Poetry of the Times
Advertisement
If you have read my poems you know
I am a man who rides trains facing backwards,
which is how I read books of poetry,
last poem first, the way I will read
the lesions on your arms
like lines from a tattered timetable
as we follow your tracks
back to that sunrise at the station
when your creases were sharp
and your wallet bulged with big bills,
her perfume clinging to your collar,
your dark eyes dancing down a line
toward a future you never imagined
would include this morning with me.
Articles in this issue
about 19 years ago
Clinical Depression: Complexities of Diagnosis and Managementabout 19 years ago
The Substance Abuse Handbookabout 19 years ago
Placebo Effects on Pharmacotherapy Outcomes in Major Depressionabout 19 years ago
Never-Ending Winter: Chronic Depressionabout 19 years ago
SSRIs and Pregnancy: Putting the Risks Into Perspectiveabout 19 years ago
Can We Predict Response to Antidepressants?about 19 years ago
Not Obsolete: Continuing Roles for TCAs and MAOIsAdvertisement
Related to this article

FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.

Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.

UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.

When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.

The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.

A psychiatry resident and APA Diversity Leadership Fellow explains how social history, open talk about stigma, and bilingual videos can widen access to care.

Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Evidence-Based Ethical Principles for Long-Acting Injectable Antipsychotic Use
2
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
3
Sleep Disruption and Alzheimer Disease: A Bidirectional, Treatable Relationship
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5

